ADC as therapy response marker for pancreatic ductal adenocarcinoma in genetically engineered mice
M Trajkovic-Arsic, I Heid, I Esposito, K Steiger, N Teichmann, A Steingötter, D Menne, A Scholz, EJ Rummeny, J Siveke, R Braren · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · 2013 · Heft 04
Bibliografische Angaben
Zusammenfassung
Ziele: High chemoresistance due to tumor heterogeneity is a hallmark of pancreatic ductal adenocarcinoma (PDAC). Non-invasive imaging parameters that allow early identification of individual therapy responsive tumors or tumor subregions and facilitate therapy choice are missing. Here we report on Apparent Diffusion Coefficient (ADC) as early therapy response marker in genetically engineered mouse models of pancreatic cancer. Methode: Ptf1a+/Cre;Kras+/LSL-G12D;p53LoxP/LoxP mice develop moderately differentiated PDAC that recapitulates well stroma rich human PDAC. Two chemotherapies were applied: standard of care…
